癌分子医学专题 |
|
|
|
|
贝伐珠单克隆抗体联合化疗用于Her2阴性乳腺癌患者新辅助治疗的meta分析 |
韩瑞, 王冠英, 张玉姣, 赵新汉 |
西安交通大学医学院第一附属医院肿瘤内科, 陕西 西安 710061 |
|
Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials |
HAN Rui, WANG Guanying, ZHANG Yujiao, ZHAO Xinhan |
Department of Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China |
[1] |
FISHER B, BROWN A, MAMOUNAS E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 15(7):2483-2493.
|
[2] |
FISHER B, BRYANT J, WOLMARK N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998, 16(8):2672-2685.
|
[3] |
GIANNI L, BASELGA J, EIERMANN W, et al. Phase Ⅲ trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer[J]. J Clin Oncol, 2009, 27(15):2474-2481.
|
[4] |
HUNT K K, YI M, MITTENDORF E A, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients[J]. Ann Surg, 2009, 250(4):558-566.
|
[5] |
BEAR H D, ANDERSON S, SMITH R E, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2006, 24(13):2019-2027.
|
[6] |
LIEDTKE C, MAZOUNI C, HESS K R, et al.Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8):1275-1281.
|
[7] |
KONG X, MORAN M S, ZHANG N, et al.Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients[J]. Eur J Cancer, 2011, 47(14):2084-2090.
|
[8] |
VON MINCKWITZ G, KVMMEL S, VOGEL P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial[J]. J Natl Cancer Inst, 2008, 100(8):542-551.
|
[9] |
MILLER K, WANG M, GRALOW J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med, 2007, 357(26):2666-2676.
|
[10] |
BEAR H D, TAILG G, RASTOGI P, et al.Bevacizumab added to neoadjuvant chemotherapy for breast cancer[J]. N Engl J Med, 2012, 366(4):310-320.
|
[11] |
HIGGINS J P, ALTMAN D G, GOTZSCHE P C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials[J]. BMJ, 2011, 343:d5928.
|
[12] |
EARL H M, HILLER L, DUNN J A, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer(ARTemis): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2015, 16(6): 656-666.
|
[13] |
VON MINCKWITZ G, EIDTMANN H, REZAI M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012, 366(4):299-309.
|
[14] |
SIKOV W M, BERRY D A, PEROU C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(11):13-21.
|
[15] |
ENGEBRAATEN O, VASKE C, KROHN M, et al. Molecular response in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: results from NeoAva-A randomized phase Ⅱ study[abstract][J]. Cancer Res, 2013, 73(24 Suppl): Abstract nr P4-14-02.
|
[16] |
HURVITZ S A, HEGDE P, BOSSERMAN L, et al. Molecular changes in breast tumors following bevacizumab-based treatment: final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage Ⅱ or Ⅲ breast cancer[abstract][J]. Cancer Res, 2012, 72(8 Suppl):Abstract nr 1385.
|
[17] |
MIEOG J S, VAN DER HAGE J A, VAN DE VELDE C J.Preoperative chemotherapy for women with operable breast cancer[J]. Cochrane Database Syst Rev, 2007, 18(2):CD005002.
|
[18] |
MILLER K, WANG M, GRALOW J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med, 2007, 357(26):2666-2676.
|
[19] |
MILES D W, CHAN A, DIRIX L Y, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the firstline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2010, 28(20):3239-3247.
|
[20] |
ROBERT N J, DIÉRAS V, GLASPY J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer[J]. J Clin Oncol, 2011, 29(10):1252-1260.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|